Rennova Health Launches Pharmacogenetics Testing Through Its Medytox Diagnostics Subsidiary

Download as PDF

Partners with Genomas to offer the revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs

WEST PALM BEACH, Fla.-- Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAW), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the launch of a series of pharmacogenetics tests that are performed via an FDA-approved in vitro diagnostic (IVD) genotyping kit.

This new service, available through the Company’s Medytox Diagnostics, Inc. subsidiary, analyzes DNA to determine a patient’s capacity to metabolize certain drugs and provides practitioners with a basis to tailor treatments to an individual’s specific genetic makeup.

This type of personalized treatment allows for superior patient outcomes and helps to reduce healthcare system costs by properly diagnosing and treating each and every patient from the inception of their illness.

To perform this service Medytox has partnered with Genomas, Inc. and its founder Gualberto Ruaño, M.D. Genomas, with headquarters in Hartford, Conn., is a biomedical company delivering personalized medicine to modern clinical practice. It has developed the revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease and diabetes. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance, ultimately reducing health care costs.

"Securing the ability to provide this modern DNA analysis and interpretation further demonstrates our commitment to expand the diagnostic solutions we offer to medical providers," remarked Seamus Lagan, CEO of Rennova Health, Inc. "Using a FDA-approved IVD genotyping kit to provide the diagnostic and decision support to alert physicians to possible drug interactions will assist our customers with administration of certain drugs and help them provide better patient care and outcomes.”

Dr. Ruaño serves on advisory committees of the National Academy of Clinical Biochemistry instituting guidelines for pharmacogenetic testing in the clinical laboratory. He is also Director of Genetics Research at Hartford Hospital and holds Adjunct Professorships on the medical faculties at George Washington University and the University of Puerto Rico. He is a Fellow of the National Academy of Clinical Biochemistry and of the American Institute for Medical and Biological Engineering.

About Rennova Health, Inc.

Rennova Health, Inc. (NASDAQ: RNVA) provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcome. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information about Rennova Health, Inc., visit www.rennovahealth.com.

Rennova Health
Sebastien Sainsbury, 561-666-9818
ssainsbury@rennovahealth.com
or
Investors
LHA
Kim Golodetz, 212-838-3777
Kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
Bvoss@lhai.com

Source: Rennova Health, Inc.

Released March 2, 2016